Guizhi Zhu
Overview
Explore the profile of Guizhi Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
3768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Liu X, Shen T, Wang Q, Zhou S, Yang S, et al.
Nat Biomed Eng
. 2025 Feb;
9(2):249-267.
PMID: 39920212
Messenger RNA vaccines have shown strong prophylactic efficacy against viral infections. Here we show that antigen-encoding small circular RNAs (circRNAs) loaded in lipid nanoparticles elicit potent and durable T cell...
2.
Ainslie K, Bowers A, Chichewicz R, Collier L, Doorn J, Frei C, et al.
AAPS J
. 2025 Feb;
27(1):41.
PMID: 39904863
On October 29, 2024, a virtual meeting, brought together chairs and vice chairs from several research-oriented U.S. Schools of Pharmacy to discuss the current landscape of pharmaceutical sciences, advocacy strategies,...
3.
Wang Q, Su T, Cheng F, Zhou S, Liu X, Wang M, et al.
bioRxiv
. 2024 Nov;
PMID: 39574605
Protein/peptide subunit vaccines are promising to promote the tumor therapeutic efficacy of immune checkpoint blockade (ICB). However, current protein/peptide vaccines elicit limited antitumor T cell responses, leading to suboptimal therapeutic...
4.
Zhou S, Su T, Cheng F, Cole J, Liu X, Zhang B, et al.
Mol Ther Nucleic Acids
. 2024 Feb;
35(1):102126.
PMID: 38352859
Activating cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) holds great potential for cancer immunotherapy by eliciting type-I interferon (IFN-I) responses. Yet, current approaches to cGAS-STING activation rely on STING agonists,...
5.
Zhou S, Cheng F, Zhang Y, Su T, Zhu G
Acc Chem Res
. 2023 Oct;
56(21):2933-2943.
PMID: 37802125
The cyclic GMP-AMP synthase-stimulator interferon gene (cGAS-STING) pathway is an emerging therapeutic target for the prophylaxis and therapy of a variety of diseases, ranging from cancer, infectious diseases, to autoimmune...
6.
Su T, Zhou S, Yang S, Humble N, Zhang F, Yu G, et al.
Theranostics
. 2023 Aug;
13(13):4304-4315.
PMID: 37649594
Glioblastoma multiforme (GBM) is the most common and lethal type of adult brain cancer. Current GBM standard of care, including radiotherapy, often ends up with cancer recurrence, resulting in limited...
7.
Zhou S, Su T, Cheng F, Cole J, Liu X, Zhang B, et al.
bioRxiv
. 2023 Jul;
PMID: 37502970
Current cancer immunotherapy (e.g., immune checkpoint blockade (ICB)) has only benefited a small subset of patients. Cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) activation holds the potential to improve cancer...
8.
Cheng F, Su T, Zhou S, Liu X, Yang S, Lin S, et al.
Sci Adv
. 2023 Jul;
9(28):eade6257.
PMID: 37450588
Current cancer immunotherapy [e.g., immune checkpoint blockade (ICB)] only benefits small subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In situ tumor vaccination can reduce TME immunosuppression and...
9.
Cheng F, Su T, Liu Y, Zhou S, Qi J, Guo W, et al.
Adv Sci (Weinh)
. 2023 Jul;
10(26):e2302575.
PMID: 37435620
Rheumatoid arthritis (RA) is a systemic autoimmune disease with pathogenic inflammation caused partly by excessive cell-free DNA (cfDNA). Specifically, cfDNA is internalized into immune cells, such as macrophages in lymphoid...
10.
Su T, Cheng F, Pu Y, Cao J, Lin S, Zhu G, et al.
Chem Eng J
. 2023 Jun;
411.
PMID: 37304676
Cancer has been one of the major healthcare burdens, which demands innovative therapeutic strategies to improve the treatment outcomes. Combination therapy hold great potential to leverage multiple synergistic pathways to...